New injection aims to tame stubborn autoimmune diseases
Disease control
Recruiting now
This early-stage study tests a new drug, GT801, in 22 adults with moderate to severe autoimmune diseases that haven't responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will also look for signs that the drug helps control the…
Phase: EARLY_PHASE1 • Sponsor: Vivacta Biotechnology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 18, 2026 11:47 UTC